- On October 15, Eiger announced results of a Toronto General Hospital investigator-sponsored study in outpatients with mild to moderate COVID-19.
- As was seen with the Regeneron data for its monoclonal antibody cocktail, patients with a high baseline viral load demonstrated a statistically significant benefit in time to viral clearance.
- Given that lambda is well tolerated and easy to administer, I would expect the drug to become widely used as first line therapy if further studies support these results.
- In a July article, I suggested that Eiger could achieve EPS exceeding $25 per share with successful commercialization of lambda for COVID-19.
For further details see:
Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive